Patachi B, Jensen KH, Gothelf A, Bernsdorf M, Friborg J, Kristensen CA. Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data. AO [Internet]. 2025 Jan. 28 [cited 2025 Feb. 22];64:143-6. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/42128